FDA issues EUA for Eli Lilly’ monoclonal antibody COVID-19 treatment
The Food and Drug Administration Nov. 10 issued an emergency use authorization for Eli Lilly and Company’s monoclonal antibody therapy, bamlanivimab.
The EUA authorizes the product’s use, but only in outpatient settings; additionally, it sets forth the type of patients eligible to receive the treatment, the drug’s storage requirements and a brief overview of how distribution will work.
Operation Warp Speed will begin to distribute nearly 80,000 vials of this therapy today, with most hospitals anticipated to receive their allocation tomorrow or Thursday.
Related News Articles
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…